ProQR Therapeutics
PRQR
46 hedge funds and large institutions have $111M invested in ProQR Therapeutics in 2020 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 10 closing their positions.
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
10% more funds holding
Funds holding: 42 → 46 (+4)
3.19% less ownership
Funds ownership: 55.87% → 52.68% (-3.2%)
17% less capital invested
Capital invested by funds: $134M → $111M (-$23.3M)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
97% less call options, than puts
Call options by funds: $2K | Put options by funds: $71K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.37M |
| 2 |
KA
Kerrisdale Advisers
Miami,
Florida
|
+$1.91M |
| 3 |
JP Morgan Chase
New York
|
+$1.2M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$1.08M |
| 5 |
Renaissance Technologies
New York
|
+$820K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$10.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.34M |
| 3 |
BlackRock
New York
|
-$1.93M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$193K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$191K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| – | -$19K | -3,964 | Closed |
|
|
CAL
52
Capital Analysts LLC
Fort Washington,
Pennsylvania
| – | -$2K | -500 | Closed |
|
|
S
53
SignatureFD
Atlanta,
Georgia
| – | -$2K | -431 | Closed |
|
|
PCM
54
Penserra Capital Management
Orinda,
California
| – | -$2K | -426 | Closed |
|
|
PA
55
Parallel Advisors
San Francisco,
California
| – | -$1K | -308 | Closed |
|
56
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -246 | Closed |
|
PRQR Hedge Fund Activity: Q4 2020 in Review
46 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2020, worth a combined $111M — down 17% from $134M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PRQR positions and 10 closed out — a net gain of 4 holders — while 8 added to existing stakes and 14 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.37M. The largest seller was Aquilo Capital Management, exiting entirely with an estimated $10.9M sold.
- 46 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2020, up from 42 in Q3 2020.
- Funds reported $111M of ProQR Therapeutics stock for Q4 2020, down 17% quarter-over-quarter.
- 14 funds opened new ProQR Therapeutics positions in Q4 2020 and 10 closed out, a net change of +4 holders.
- The largest ProQR Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $3.37M added.
- The largest ProQR Therapeutics seller in Q4 2020 was Aquilo Capital Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2020.